The SPDR S&P Pharmaceuticals ETF received Form 13F filings regarding institutional holdings with the Securities and Exchange Commission on May 27, 2026.
3 reports, 2 independent
Updated May 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The SPDR S&P Pharmaceuticals ETF received Form 13F filings regarding institutional holdings with the Securities and Exchange Commission on May 27, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.SPDR S&P Pharmaceuticals ETF filed 13F reports with the SEC on May 27, 2026.1 source
McKesson Corporation filed 13F reports regarding institutional holdings.1 source
Keep exploring
The entities involved
-
Securities and Exchange Commission
government agency of the Philippines
-
McKesson Corporation
U.S. healthcare supplies
Nothing else this week.
Related events
- The Securities and Exchange Commission received Form 13F filings on November 6, 2026.
- The SEC is tracking 13F filings submitted by institutional investors, involving Omnicom Group.
- Verus Financial Partners Inc. filed its required 13F report with the Securities and Exchange Commission on November 1, 2026.
- GT Biopharma filed with the SEC regarding institutional investment, and its stock traded on the Nasdaq exchange.
- Defiance S&P 500 Enhanced Options & 0DTE Income ETF filed Form 13F with the SEC.